{"id":562936,"title":"Guidance to Establish Equivalence or Relative Potency of Safety and Efficacy of a Second Entry Short-Acting Beta2-Agonist Metered Dose Inhaler (MDI) [Health Canada, 1999] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-02-16","captureTimestamp":"2026-02-16T10:30:38.995000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/inhalers/guidance-establish-equivalence-relative-potency-safety-efficacy-second-entry-short-acting-beta2-agonist-metered-dose-inhaler.html","snippet":"Guidance to Establish Equivalence or Relative Potency of Safety and Efficacy of a Second Entry Short-Acting Beta2-Agonist Metered Dose Inhaler (MDI) [Health Canada, 1999] (PDF Version - 76 K) Contact: BCANS Enquiries Therapeutic Products Programme Holland Cross, Tower \"B\" 2 nd…","rawSnapshotUrl":"/api/snapshots/raw/562936","browseUrl":"https://replay.healtharchive.ca/job-6/20260216103038/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/inhalers/guidance-establish-equivalence-relative-potency-safety-efficacy-second-entry-short-acting-beta2-agonist-metered-dose-inhaler.html#ha_snapshot=562936","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}